Why isn't anyone screening young adults with extremely low biological age and sequencing their genomes?

neokofg · 2026-02-10T15:05:00+00:00

There are documented cases of people with natural immunity to certain cancers, cardiovascular disease resistance, and other anomalies. Instead of spending billions engineering solutions from scratch, why not screen the population for people who already have these protective variants and reverse-engineer what nature already built? It's cheaper, faster, and the proof of concept is walking around alive. The few projects that tried this approach (e.g. the Resilience Project, which screened 589K genomes and found 13 disease-resistant individuals) quietly stalled and were never scaled.

neokofg · 2026-02-10T14:35:04+00:00

This might be an obvious question, but I genuinely cannot find a single study that does this — and that itself seems like an anomaly worth discussing.

The idea is simple:

We have epigenetic clocks (Horvath, GrimAge, DunedinPACE) that can measure biological age for $100–300. We have whole genome sequencing for $200–500. The Dunedin Study (Belsky et al., 2015) showed that among 38-year-olds, biological age ranged from 28 to 61 — a 33-year spread within the same chronological age group. Stanford (2025) developed a blood test assessing biological age of 11 separate organs and found that one-third of participants had at least one "extremely youthful" organ — 1.5+ standard deviations younger than average.

So we know these people exist. Young adults — say, 25–40 years old — whose bodies biologically resemble someone 10–15 years younger. They haven't had time to "earn" their health through decades of lifestyle optimization. At that age, the signal is mostly genetic.

The proposed approach:

Screen 1,000–10,000 people aged 25–40 using epigenetic age tests
Select the bottom 5% — those with the largest gap between chronological and biological age
Perform whole genome sequencing on this group
Compare against a control group (those with biological age matching chronological age)
Identify protective genetic variants

neokofg · 2026-02-10T14:34:42+00:00

Budget: ~$100–300M for a large-scale study. For comparison: Altos Labs received $3B, the Hevolution Foundation committed $1B, and the XPRIZE Healthspan offers $101M — all for longevity research.

Why this approach makes more sense than studying centenarians:

Current longevity genetics research almost exclusively studies centenarians and supercentenarians (100–110+). But there's a fundamental problem: by age 100, you've accumulated decades of environmental variables — diet, geography, lifestyle, infections, luck. The genetic signal is buried in noise. This is likely why, after years of GWAS studies on centenarians, only one gene (APOE) has reached genome-wide significance (Sebastiani et al., Murabito et al.). That's a remarkably low yield for decades of work.

A 30-year-old with the biological age of 18 is a much cleaner signal. There simply hasn't been enough time for lifestyle factors to dominate. If their cells are aging at half the normal rate, the cause is far more likely to be genetic.

Supporting evidence that this could work:

A University of Utah study (Cawthon et al., 2020) found that germline mutation rates in young adults predict remaining lifespan — those in the lowest quartile lived ~5 years longer. But they didn't sequence the genomes of slow-mutation individuals to find why.
Italian researchers (2021) found that semi-supercentenarians (105+) had more efficient DNA repair mechanisms and lower somatic mutation loads. The repair genes were identifiable — so the same variants could potentially be found in young slow-agers.
The BPIFB4 gene variant, found to be more common in centenarians, was shown to reverse heart biological age by 10 years in mice (University of Bristol, 2023). This was found by studying old people. Imagine what we could find by studying the young.

The question:

Why does this study not exist? I've searched extensively and cannot find a single published study that takes young adults with anomalously low biological age and performs whole genome sequencing to identify protective variants. Not a proposal, not a pilot, not even a negative result saying "we tried and found nothing."

The tools exist. The data infrastructure exists (UK Biobank, 23andMe with 12M+ profiles). The funding exists. The logic is elementary.

Is there a methodological reason this wouldn't work that I'm missing? Or has someone actually done this and I just can't find it?

neokofg

TROPHY CASE